Drugs / Terbium 161- PSMA I&T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07441837 | Jul 2026 → Aug 2028 expected | prostate cancer | Ankara University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terbium 161- PSMA I&T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441837 ↗ |
| Modality | Other / unclassified | “Radionuclide treatment” NCT07441837 ↗ |
| Route | Intravenous | “administered by slow intravenous injection” NCT07441837 ↗ |